Our Story
Lilly Ventures has its roots in
the scientific tradition of
Eli Lilly and Company. Our
investment philosophy drives
us to seek great companies
with compelling life science innovations.
Our Team
Our collaborative partnership
leverages the collective
experience, deep expertise,
and networks of our
investment professionals for
the benefit of our portfolio
companies.
Our News
Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week
April 20, 2017
Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week
view full storyFORMA Therapeutics delivers two key objectives in collaboration with Celgene Corporation
April 10, 2017
FORMA Therapeutics delivers two key objectives in collaboration with Celgene Corporation to advance protein homeostasis medicines to benefit patients.
view full storyInnocrin Appoints Fred Eschelman as CEO and is Granted Fast Track for Seviteronel
April 6, 2017
Innocrin Appoints Fred Eschelman as CEO and is Granted Fast Track for Seviteronel for Cancer Treatment
view full storySutro ADC Targeting CD74 Eradicates BCell Hematologic Malignancy
April 3, 2017
Sutro ADC Targeting CD74 Eradicates BCell Hematologic Malignancy, Prolongs Survival in Tumor Models
view full storyAeglea Biotherapeutics to Present Preclinical Data for AEB1102
March 29, 2017
Aeglea Biotherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting
view full storyAeglea Biotherapeutics to Present Topline Data
March 23, 2017
Aeglea Biotherapeutics to Present Topline Data from Phase 1 Trial of AEB1102
view full storyFORMA Therapeutics announces achievement of first clinical development milestone in partnership with Boehringer
March 17, 2017
FORMA Therapeutics announces achievement of first clinical development milestone in partnership with Boehringer
view full storyCoherus Biosciences announces CHS-1420 pharmacokinetic clinical bioequivalence study meets primary endpoint
March 2, 2017
Coherus Biosciences announces CHS-1420 pharmacokinetic clinical bioequivalence study meets primary endpoint
view full storySymic Bio Announces Last Patient Enrolled in SHIELD Trial
February 24, 2017
Symic Bio Announces Last Patient Enrolled in SHIELD Trial of SB-030 for Interventions in Peripheral Artery Disease
view full storyFORMA Therapeutics awarded grant from the Michael J. Fox foundation for Parkinson's research
February 21, 2017
FORMA Therapeutics awarded grant from the Michael J. Fox foundation for Parkinson’s research
view full storyProtagonist Therapeutics Presents Data on Oral Peptide
February 17, 2017
Protagonist Therapeutics Presents Data on Oral Peptide
view full storyCoherus prices public offering of common stock
February 8, 2017
Coherus prices public offering of common stock
view full storyCoherus Biosciences announces positive topline 24-week treatment phase three results
January 10, 2017
Coherus Biosciences announces positive topline 24-week treatment phase three results for CHS-1420 (HUMIRA® biosimilar candidate) in patients with psoriasis
view full storyAllergan Enters Parkinson’s Disease Through Option Arrangement with LTI
January 9, 2017
Allergan Enters Parkinson’s Disease Through Option Arrangement with Lysosomal Therapeutics Inc. (LTI) for its Potential First-In-Class Breakthrough Compounds
view full storyViamet Reports Positive Results from RENOVATE
January 6, 2017
Viamet Reports Positive Results from RENOVATE Phase 2b Trial of Oral VT-1161 in Onychomycosis
view full storyViamet Reports Positive Results from REVIVE
January 6, 2017
Viamet Reports Positive Results from REVIVE Phase 2b Trial of Oral VT-1161 in Recurrent Vulvovaginal Candidiasis
view full storyCavion Raises $26.1 MM Series A Financing
January 6, 2017
Cavion Raises $26.1 MM Series A Financing
view full storyNimbus Appoints Mark Ashwell, Ph.D., as Head of Chemistry
January 5, 2017
Nimbus Appoints Mark Ashwell, Ph.D., as Head of Chemistry
view full storySurface Welcomes Daniel S. Lynch as Chairman of Board
January 4, 2017
Surface Oncology Welcomes Industry Leader Daniel S. Lynch as Chairman of Board of Directors
view full storyInnocrin Presents Data SABCS 2016 Poster
December 13, 2016
Innocrin Pharmaceuticals Presents Data SABCS 2016 Poster
view full storySutro ADC Targeting CD74 Exhibits Potent Anti-tumor Activity
December 6, 2016
Sutro ADC Targeting CD74 Exhibits Potent Anti-tumor Activity
view full storyNimbus Therapeutics announces $200M milestone
November 1, 2016
Nimbus Therapeutics announces $200 million milestone from Gilead Sciences
view full storyInnocrin Appoints Edwina Baskin-Bey MD as CMO and Expands BCa study
October 5, 2016
Innocrin Appoints Edwina Baskin-Bey MD as Chief Medical Officer and Expands BCa study
view full story